Patents Examined by Jennifer Shaver
  • Patent number: 5601830
    Abstract: The isolation and characterization of a novel staphylococcal enterotoxin designated SEH is described. A process for high-yield generation of substantially pure SEH and antibodies specific thereto is described, as is construction of an immunoassay for detection and quantification of SEH within a sample.
    Type: Grant
    Filed: March 31, 1995
    Date of Patent: February 11, 1997
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Yi C. Su, Amy C. Lee Wong
  • Patent number: 5599541
    Abstract: Peptide sequence capable of initiating delayed hypersensitivity reactions of different intensity in the presence of living bacteria as opposed to dead bacteria of the Mycobacterium tuberculosis complex. The sequence is characterized in that it comprises no more than 0.5% by weight of tyrosine, phenylalanine, methionine, histidine, arginine and cysteine amino acids. The invention also concerns the diagnostic and therapeutic applications of a peptide or protein comprising said sequence.
    Type: Grant
    Filed: October 17, 1994
    Date of Patent: February 4, 1997
    Assignee: Institut Pasteur
    Inventors: Gilles Marchal, Felix Romain
  • Patent number: 5593678
    Abstract: Utility of protein phosphatase inhibitors to protect teleost fish from microorganismic pathogens is disclosed. The present invention provides pharmaceutical compositions, kits, and methods of therapeutic and prophylactic treatments comprising sodium orthovanadate or vanadate-mimetic protein phosphatase inhibitors to protect fish, for example, catfish, from infection and disease caused by microorganismic pathogens, e.g., Edwardsiella. Sodium orthovanadate, a protein phosphatase inhibitor, and vanadate-mimetic protein phosphatase inhibitors activate in vitro and in vivo the cytotoxicity of teleost nonspecific cytotoxic cells (NCC).
    Type: Grant
    Filed: October 11, 1994
    Date of Patent: January 14, 1997
    Assignee: University of Georgia Research Foundation
    Inventors: Donald L. Evans, Liliana Jaso-Friedmann
  • Patent number: 5583204
    Abstract: An assay to confirm the presence of antibodies to T. cruzi in a test sample. The assay comprises detecting the presence of antibody to three T. cruzi antigens, Gp 90, Gp 60/50 and LPPG in a test sample. The presence of antibody in the test sample to at least two of three T. cruzi antibodies is indicative of a confirmed reactive sample. Also provided are diagnostic reagents for detection of T. cruz, a process for purifying GP 60/50, a process for linking a protein and LPPG, and diagnostic test kits for use when assaying for antibodies to T. cruzi.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: December 10, 1996
    Assignee: Abbott Laboratories
    Inventors: Martin A. Winkler, Alfred A. Pan
  • Patent number: 5571531
    Abstract: A particulate carrier for an agent comprising a solid core of a polysaccharide and a proteinaceous material and an organometallic polymer bonded to the core is provided. The agent has a biological activity, such as immunogenicity, and may comprise the proteinaceous material or be a separate component of the core. Polysaccharide cores include dextran, starch, cellulose and derivatives thereof and the organometallic polymer includes silicones including substituted silicones. The particulate carriers are useful for delivering agents to the immune system of a subject by mucosal or parenteral administration to produce immune responses, including antibody responses.
    Type: Grant
    Filed: May 18, 1994
    Date of Patent: November 5, 1996
    Assignee: McMaster University
    Inventors: Mark R. McDermott, Michael A. Brook, Philippa L. Heritage, Brian J. Underdown, Lesley M. Loomes, Jianxiong Jiang
  • Patent number: 5559213
    Abstract: The present invention is a physiologically active, substantially non-immunogenic water soluble polyethylene glycol protein conjugate having the same utility as the protein which forms the conjugate, without having the same properties of producing an immunogenic response possessed by the protein which forms this conjugate.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: September 24, 1996
    Assignee: Hoffmann-La Roche Inc.
    Inventors: John Hakimi, Patricia Kilian, Perry Rosen
  • Patent number: 5554372
    Abstract: The present invention comprises adjuvants which, when admixed with an antigen and administered into a human or animal, will induce a more intense immune response to the antigen than when the antigen is administered alone. In many cases, the adjuvant that is described as the present invention will increase overall titer of antibodies of a specific isotype which are specific for the antigen. For example, in mice, when the adjuvant of the present invention is admixed with a conventional antigen, the isotype that is induced in the mouse is changed from a predominantly IgG1 isotype to the more protective IgG2 isotype and, in some cases, IgG3 isotype. Thus, by practicing the present invention, one can improve the overall protective effect of conventional vaccines.
    Type: Grant
    Filed: April 11, 1995
    Date of Patent: September 10, 1996
    Assignee: Emory University
    Inventor: Robert L. Hunter
  • Patent number: 5552285
    Abstract: Compositions, immunoassay methods, and kits are provided for detecting antibodies specific for oxidized DNA bases, including diagnosis of inflammatory diseases and related conditions, as well as monitoring of the progress or therapy of such diseases and conditions.
    Type: Grant
    Filed: July 1, 1994
    Date of Patent: September 3, 1996
    Assignee: New York University
    Inventor: Krystyna Frenkel